CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
GSK1292263 +2 moredrug
Likely dose
GSK1292263 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01119846
NCT01119846Phase 2Completed
CompareCT.gov

A Study in Type II Diabetic Subjects of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Compound Alone and When Co-administered With Sitagliptin or Metformin

GlaxoSmithKline·interventional·Posted May 10, 2010·Updated Jan 17, 2018

In Brief

A Phase 2 clinical trial evaluating GSK1292263, GSK1292263 matching placebo, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 100 participants across 7 sites.

Detailed Summary

The purpose of this study is to see if GSK1292263 is safe and well-tolerated when administered to type 2 diabetics, and to get preliminary information about whether it may be effective in the treatment of type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 10, 2010
Enrollment StartJun 5, 2009
Primary CompletionMar 19, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.1 years ago

Interventions

GSK1292263drug

GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.

GSK1292263 matching placebodrug

Matching placebo to active drug GSK1292263

Sitagliptindrug

Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with "277" on one side.